Title:

Reasons for non-attendance to cervical cancer screening and acceptability of HPV self-sampling among Bruneian women: A cross-sectional study.

Authors:

Liling Chaw[1*], Shirley HF Lee[1], Nurul Iffah Hazwani Ja'afar[1], Edwin Lim[2], Roslin Sharbawi[3]

Affiliations:

1) PAPRSB Institute of Health Sciences, Gadong, Brunei Darussalam.
2) Histopathology Department, RIPAS Hospital, Ministry of Health, Brunei Darussalam
3) Community Maternal Health Service, Department of Health Services, Ministry of Health, Bandar Seri Begawan, Brunei Darussalam

*** Corresponding Author:**

Email: liling.chaw@ubd.edu.bn (LC)

Running title:

Reasons for cervical cancer screening non-attendance and HPV self-sampling acceptability in Brunei

Number of words: 327 words (abstract), 4387 words (manuscript, excluding references)

Abstract

Objective: Uptake for cervical cancer screening remains well below the recommended rate of 80%. We conducted a pilot study to determine the reasons for non-attendance and explore their acceptance of human papillomavirus (HPV) self-sampling as an alternative to Pap test.

Methods: A two-part cross-sectional study was conducted at a health centre in Brunei, from January to December 2019. Women who were eligible for a Pap test but who either never or did not have one within the past four years were conveniently recruited. Participants were first asked to complete a paper-based survey on their reasons for screening non-attendance, and then invited for HPV self-sampling. Results were analysed using descriptive and inferential statistics.

Result: We enrolled 174 screening non-attendees, out of which 97 (55.7%) also participated in HPV self-sampling. The main reasons for not attending Pap test screening were fear of bad results (16.1%, n = 28); embarrassment (14.9%, n = 26) and lack of time due to home commitments (10.3%, n = 18). When compared to those who agreed to participate in HPV self-sampling, those who declined were significantly older (p = 0.002) and less likely to agree that they are susceptible to cervical cancer (p = 0.023). They preferred to receive Pap-test related information from healthcare workers (59.0%, n = 155), social messaging platforms (28.7%, n = 51) and social media (26.4%, n = 47). HPV self-sampling kits were positively-received, where > 90% agreed on its ease and convenience. Nine of 97 participants (9.3%) tested positive for hr-HPV, out of which eight were non-16/18 HPV genotypes.

Conclusion: Our findings suggest that promoting knowledge on cervical cancer, the benefits of screening and clarifying any misconceptions of Pap test results would help increase screening uptake

among Bruneian non-attendees. Response to HPV self-sampling was highly positive, implying its receptiveness in the local setting. Our high detection of non-16/18 HPV genotypes suggest high prevalence of other hr-HPV genotypes in Brunei. Larger studies can be conducted to further validate our findings.

Keywords: Cervical cancer screening, HPV self-sampling, women's health, Brunei

Introduction

Cervical cancer is highly preventable but still remains one of the most common cancers among women worldwide, accounting for 6.6% of all female cancer deaths in 2018 [1]. Cervical cancer screening has drastically reduced the incidence of invasive cervical cancer in countries that have implemented such screening programmes [2], which traditionally involves the use of the standard Papanicolaou (Pap) test. However, as specific high-risk human papillomavirus subtypes (hr-HPV) are known to be a causative agent, the use of HPV self-sampling is becoming either an alternative or a complement to the Pap test to increase screening uptake rate [3], particularly to promote women's participation among screening non-attendees [4].

HPV self-sampling were found to be highly acceptable among non-attendees [5,6]. Repeated HPV self-sampling and testing were shown to increase screening uptake [3,4,7], and also resulted in at least two-fold higher detection rate of high-grade cervical intraepithelial neoplasia (CIN2+) when compared to Pap test [8,9]. In addition, HPV self-sampling results exhibit similar sensitivity and specificity compared to results from samples taken by trained professionals [10]. At the national level, early detection through organised screening had been shown to reduce cervical cancer morbidity and mortality in countries such as the United Kingdom and Australia [11,12]. Both countries have further strengthened their national cervical cancer screening programme by replacing cytological test with HPV test as the primary screening test.

Brunei Darussalam (population 459,500) is a small Southeast Asian country with a predominant Muslim population and a crude birth rate of 15.3 per 1,000 population [13]. Within this region, it has one of the highest age-standardised incidence rate (ASR) for cervical cancer: 20.6 in Brunei when compared to 10.5 and 7.7 in Malaysia and Singapore, respectively [14]. Brunei has initiated a national cervical cancer prevention and control programme since 2009, which include setting up the

National Pap Test Registry, organising cervical screening through periodic mail invitations for sexually-active women aged 20 to 65 years, replacing the conventional Pap test with liquid-based cytology, and initiating HPV vaccination for school-aged female adolescents [15]. However, despite cervical screening being offered free of charge, the national screening coverage rate remains low at 44% in 2018 (unpublished data). Non-attendees of cervical screening are at increased risk of developing cervical cancer; hence the importance of reaching these women [16]. Reasons for screening non-attendance can also vary across settings [17,18].

With Brunei's relatively high incidence of cervical cancer and low screening uptake, we conducted a pilot study to explore the reasons behind non-attendance and assess the acceptability of HPV self-sampling as a possible alternative to the Pap test among non-attendees. Study findings could be used to strategise ways to improve screening coverage and provide preliminary evidence towards implementing HPV testing as the primary screening test for cervical cancer in Brunei.

Methods

Study design and data collection

We conducted a two-part cross-sectional survey at Jubli Perak Sengkurong Health Center (JPSHC), from January to December 2019. JPSHC is a government-funded health centre located in Brunei-Muara District, where the majority (69.3%) of the country's population resides. This centre provides primary health care services to Mukim Sengkurong, a sub-district with about 32 000 people from various socioeconomic backgrounds.

Eligible women attending either the outpatient or child health clinic were conveniently recruited by triage nurses. The inclusion criteria were married or ever married Bruneian women between 20 and

65 years old, who never had a Pap test or did not have a Pap test within the last 4 years, and who can comprehend Brunei-Malay or English language. Women who were either pregnant, have had total hysterectomy, or with a history of malignancies were excluded.

Following recruitment, potential participants were referred to an assigned research focal person based at JPSHC. The participants were informed of the study objectives and of the two study parts; the first involving a set of self-administered questionnaires on reasons for non-attendance to routine cervical screening (Q1), and the second (optional) part involving HPV self-sampling to be performed at a later date and completing a second self-administered questionnaire on their acceptability of the self-sampling procedure (Q2).

Participants who consented to the first part of the study were asked to complete Q1 onsite. They were then given an envelope containing information on the second optional study and an instruction leaflet on the HPV self-sampling procedure. Within two weeks, they were contacted by the focal person regarding their decision to participate in the second part of the study. Those who agreed to participate were given an appointment to JPSHC. On the appointment day, a trained nurse first explained the self-sampling procedure with the aid of an online instructional video, and answered any questions or concerns. Then, participants were given a self-sampling kit and asked to perform the self-sampling procedure in the clinic. After completing the procedure, the participants were invited to complete Q2.

Questionnaires used

Two bilingual paper-based questionnaires (Brunei-Malay and English language) were used: one on the reasons for non-attendance (Q1) and another on their acceptability of the self-sampling procedure (Q2). Both questionnaires were adapted from similar studies [19,20]. They were first

translated to Brunei-Malay language by native speakers, and then back-translated to check for inconsistencies in comprehension. Both questionnaires were also pre-tested on six eligible women to assess if the questions can be easily understood. Responses from pre-testing were not included in the main analysis.

Q1 consists of 19 questions on the participant's socio-demographics; reasons for not getting Pap test; attitude and knowledge on cervical cancer; and lastly, preferred sources to acquire information about Pap test. From a prepared list of 16 options, participants were asked to select one ("Major" reason) or more reasons (categorized as "Minor" reasons) for not attending the screening programme. Responses for questions on their attitude and knowledge on cervical cancer were assessed using a five-point Likert scale, ranging from "Strongly Agree" to "Strongly Disagree". Q2 consists of 12 five-point Likert scale questions (ranging from "Strongly Agree" to "Strongly Disagree") on their experiences and opinions of the self-sampling kit.

Self-sample handling and laboratory testing

Swabs collected from the self-sampling kits were sent to an overseas laboratory (at BNH hospital, Thailand) for hr-HPV testing. The self-sampling device used was the Evalyn® brush from Rovers Medical Devices. Upon receipt at the testing laboratory, the dry Evalyn® brush was suspended in SurePath medium from which a sample was obtained for the identification of the presence of hr-HPV using the cobas HPV test (Roche, USA). Cobas HPV tests are automated qualitative *in vitro* tests for the detection of HPV DNA in patient specimens. The tests utilize amplification of target DNA by polymerase chain reaction (PCR) and nucleic acid hybridization for the detection of 14 hr-HPV types (namely genotypes 16, 18, and 12 pooled hr-HPV genotypes 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 and 68) in a single analysis. Results obtained from this test can be categorized into four groups: Negative, HPV-16 positive, HPV-18 positive, and positive for non-16/18 HPV genotypes.

Clinical management of hr-HPV positive participants

We adopted the cytology triage strategy for HPV self-sampling participants [21]. Participants with hr-HPV positive results were invited for an immediate clinic-based cytology triage test. Those found to have negative cytology results were invited for a repeat cytology triage test after six months. Those with second negative results were returned to routine cervical screening recall. Participants with any positive cytology result (defined as with Atypical Squamous Cells of Undetermined Significance or worse) were referred for colposcopic examination.

Statistical analysis

Descriptive statistics was conducted to characterize the socio-demographic characteristics of the study population, their reasons for not attending screening, their attitudes and preference for information access on such screening, as well as responses from Q2. Mann-Whitney and Fisher's exact tests were used to assess significant differences in sociodemographic characteristics between women who agreed and women declined to proceed to the HPV self-sampling part of the study. Responses for questions with the five-point Likert scale were categorized into three categories (agree, neutral, and disagree), and those with missing values were classified as neutral. Analysis was conducted using R ver. 3.6 [22]. Ethics approval was obtained from the Medical and Health Research and Ethics Committee (MHREC), Ministry of Health, Brunei Darussalam [Reference no. MHREC/MOH/2018/9(2)].

Results

A total of 174 eligible women were enrolled into the study from January to December 2019, out of which 97 (55.7%) also participated in HPV self-sampling (Figure 1). Their median age was 45 years, ranging between 23 and 65 years (Table 1). The participants were mainly of Malay ethnicity (92.5%, n = 161), married (90.2%, n = 157), and had three or more births (60.3%, n = 105). More than half of the participants had their last Pap test performed between 4 and 10 years ago (52.3%, n = 91) and have never received the HPV vaccine (54.6%, n = 95). There were significant differences between those who agreed and declined to participate in HPV self-sampling: those who declined were significantly older (p = 0.002) and more likely to have their last Pap test performed more than 10 years ago (p = 0.031).



Figure 1. Flowchart of study participants at JPHSC, Brunei (Jan – Dec 2019)

Characteristics		Total study population (n = 174) n (%)	Joined self-sampling (n = 97) n (%)	Declined self-sampling (n = 77) n (%)	p-value
Median age in years (IQR)		45 (15.25)	41.0 (17)	49.0 (14.5)	**0.002***
Age-group (in years)	20 - 24	3 (1.7)	3 (3.1)	0 (0.0)	**0.018***
	25 - 29	20 (11.5)	15 (15.5)	5 (6.5)	
	30 - 34	14 (8.1)	10 (10.3)	4 (5.2)	
	35 - 39	28 (16.1)	18 (18.5)	10 (13.0)	
	40 - 44	18 (10.3)	11 (11.3)	7 (9.0)	
	45 - 49	27 (15.5)	12 (12.4)	15 (19.5)	
	50 - 54	35 (20.1)	15 (15.5)	20 (26.0)	
	55 - 59	14 (8.1)	10 (10.3)	4 (5.2)	
	> 60	13 (7.5)	3 (3.1)	10 (13.0)	
	Missing	2 (1.1)	0 (0.0)	2 (2.6)	
Race	Malay	161 (92.5)	90 (92.8)	71 (92.2)	0.752
	Chinese	6 (3.5)	4 (4.1)	2 (2.6)	
	Other	7 (4.0)	3 (3.1)	4 (5.2)	
Education level	Primary school	16 (9.2)	10 (10.3)	6 (7.8)	0.396
	Secondary school	96 (55.2)	49 (50.5)	47 (61.0)	
	College / university	57 (32.7)	35 (36.1)	22 (28.6)	
	Missing	5 (2.9)	3 (3.1)	2 (2.6)	
Marital status	Married	157 (90.2)	91 (93.8)	66 (85.7)	0.15
	Divorced	8 (4.6)	2 (2.1)	6 (7.8)	
	Widowed	9 (5.2)	4 (4.1)	5 (6.5)	
Occupation	Housewife	64 (36.8)	39 (40.2)	25 (32.4)	0.087
	Government employee	67 (38.5)	41 (42.3)	26 (33.8)	
	Private employee	31 (17.8)	13 (13.4)	18 (23.4)	
	Retired	9 (5.2)	3 (3.1)	6 (7.8)	
	Unemployed	1 (0.6)	1 (1.0)	0 (0.0)	
	Other	2 (1.1)	0 (0.0)	2 (2.6)	
Monthly household income	< $500	27 (15.5)	15 (15.5)	12 (15.6)	0.498
	$500 < $999	27 (15.5)	12 (12.4)	15 (19.5)	
	$1000-$1999	40 (23.0)	22 (22.7)	18 (23.4)	
	$2000-$2999	19 (10.9)	14 (14.3)	5 (6.5)	
	$3000-$5000	24 (13.8)	15 (15.5)	9 (11.7)	
	>$5000	3 (1.7)	2 (2.1)	1 (1.3)	
	Missing	34 (19.5)	17 (17.5)	17 (22.0)	
Number of births	0	27 (15.5)	17 (17.5)	10 (13.0)	0.103
	1	19 (10.9)	14 (14.4)	5 (6.5)	

	2 3 or more Missing	22 (12.1) 105 (60.3) 2 (1.2)	14 (14.4) 51 (52.6) 1 (1.1)	7 (9.1) 54 (70.1) 1 (1.3)	
Last Pap test done	Never 4-10 years > 10 years Missing	41 (23.6) 91 (52.3) 36 (20.7) 6 (3.4)	29 (29.9) 48 (49.5) 15 (15.5) 5 (5.1)	12 (15.6) 43 (55.8) 21 (27.3) 1 (1.3)	**0.031***
Completed HPV vaccination	Never Yes No Missing	95 (54.6) 27 (15.5) 41 (23.6) 11 (6.3)	50 (51.6) 16 (16.5) 26 (26.8) 5 (5.1)	45 (58.4) 11 (14.3) 15 (19.5) 6 (7.8)	0.483

Table 1. Sociodemographic characteristics of the study population, including comparison between groups that agreed and declined to join HPV self-sampling. IQR = Interquartile range.

Figure 2 and Table S1 show the responses for the major and minor reasons for not attending cervical cancer screening. The top three major reasons reported were that they were “afraid of getting a bad result” (16.1%, n = 28), “feeling embarrassed being examined by a doctor or nurse” (14.9%, n = 26), and “I can't find the time as I'm too busy at home” (10.3%, n = 18). The top three minor reasons were “feeling embarrassed being examined by a doctor or nurse” (20.7%, n = 36), “I can’t find time as I’m too busy at work” (20.7%, n = 36), and “afraid of getting a bad result” (20.1%, n = 35).



Figure 2. Responses on their major and minor reasons for not attending cervical cancer screening, among non-attendees at JPSHC (Jan – Dec 2019). The x-axis indicates the percentage, and the number next to each bar indicates the actual number of responses.

When comparing top 10 major reasons for not attending screening between those who agreed and declined HPV self-sampling (Table 2), those whose major reason was “feeling embarrassed being

examined by a doctor or nurse" were significantly more likely to join self-sampling (p = 0.020). Also, those whose major reason was "afraid of getting a bad result" were significantly more likely to decline self-sampling (p = 0.034). Among those who were employed (n = 98), about a quarter (23.5%, n = 23) reported work-related reasons as their major reason for not attending screening ("I can't find the time as I'm too busy at work" and "Difficult to get permission from employer").

No.	Top ten major reasons of screening non-attendance	Total n (%)	Joined HPV self-sampling n (%)	Declined HPV self-sampling n (%)	*p*-value
1	I feel embarrassed being examined by a doctor or nurse	26 (14.9)	20 (76.9)	6 (23.1)	**0.020***
2	I am scared of pain because of previous bad experience(s)	16 (9.2)	8 (50.0)	8 (50.0)	0.825
3	I am scared of getting a bad result	28 (16.1)	10 (35.7)	18 (64.3)	**0.034***
4	I can't find the time as I'm too busy at home	18 (10.3)	12 (66.7)	6 (33.3)	0.463
5	I can't find the time as I'm too busy at work	16 (9.2)	10 (62.5)	6 (37.5)	0.759
6	Difficult to get permission from employer	8 (4.6)	5 (62.5)	3 (37.5)	1
7	I have never heard of a Pap Test	7 (4.0)	4 (57.1)	3 (42.9)	1
8	I have forgotten about it	6 (3.4)	5 (83.3)	1 (16.7)	0.229
9	I did not receive any invitation	6 (3.4)	5 (83.3)	1 (16.7)	0.229
10	Others	15 (8.6)	7 (46.7)	8 (53.3)	0.492

Table 2. The top ten major reasons of not attending cervical cancer screening at JPSHC, Brunei (Jan – Dec 2019), with comparison between those who agreed and declined HPV self-sampling. Responses from 146 participants (83.9% of the total study population) were included.

While there is a variation in the responses when asked about their health and susceptibility to disease, most agreed on the benefits of undergoing Pap test (92.0%, n = 160) and on the severity of cervical cancer (82.8%, n = 144; Table 3).

No.	Attitude questions	Agree n (%)	Neutral n (%)	Disagree n (%)
1	I believe I am healthy and free of any diseases	62 (35.6)	61 (35.1)	51 (29.3)
2	Having Pap test taken is beneficial for my health	160 (92.0)	10 (5.7)	4 (2.3)
3	Like any women, I am susceptible to develop cervical cancer	110 (63.2)	52 (29.9)	12 (6.9)
4	Cervical cancer can be severe and may lead to death	144 (82.8)	23 (13.2)	7 (4.0)

Table 3. Attitudes towards cervical cancer screening among non-attendees at JPSHC, Brunei (Jan – Dec 2019). Responses from the total study population (n = 174) were included.

When comparing the responses for each attitude question between those who agreed and declined to join HPV self-sampling (Table 4), those who agreed that they are more susceptible to develop cervical cancer were significantly more likely to join HPV self-sampling (*p* = 0.023).

No.	Attitude questions		Joined HPV self-sampling n (%)	Declined HPV self-sampling n (%)	*p*-value
1	I believe I am healthy and free of any diseases	Agree	34 (54.8)	28 (45.2)	0.984
		Neutral/ Disagree	63 (56.3)	49 (43.7)	
2	Having Pap test taken is beneficial for my health	Agree	91 (56.9)	69 (43.1)	0.464
		Neutral/ Disagree	6 (42.9)	8 (57.1)	
3	Like any women, I am susceptible to develop cervical cancer	Agree	69 (62.7)	41 (37.3)	**0.023***
		Neutral/ Disagree	28 (43.8)	36 (56.2)	
4	Cervical cancer can be severe and may lead to death	Agree	79 (54.9)	65 (45.1)	0.754
		Neutral/ Disagree	18 (60.0)	12 (40.0)	

Table 4. Comparison of the attitudes towards cervical cancer screening among non-attendees at JPSHC, Brunei (Jan–Dec 2019), between those who agreed and declined HPV self-sampling. Responses from the total study population (n = 174) were included.

Most participants responded that they would like to obtain more information about cervical cancer screening (85.6%, n = 149). The top preferred information sources were healthcare workers (59.8%, n = 104), social messaging platforms (28.7%, n = 50) and social media (26.4%, n = 46; Figure 3).



Figure 3. Preferred sources of information about cervical cancer among non-attendees at JPSHC, Brunei (Jan–Dec 2019). The x-axis indicates the percentage, and the number next to each bar indicates the number of responses. Multiple responses were allowed and responses from the total study population (n = 174) were included.

Among those who participated in self-sampling (55.7%, n = 97), their responses on the use of the self-sampling kit (Table 5) were generally positive and encouraging. A majority agreed that the instructions were clear (94.8%, n = 92), that it was easy to perform the swab (93.8%, n = 91), and that it was more convenient than the Pap test (91.7%, n = 89). They also reported their confidence in correctly getting the sample (92.8%, n = 90), would prefer to use this method next time (94.8%, n = 92), and would recommend this method to other women (93.8%, n = 91). Notably, 54.6% (n = 53) still prefer a proper Pap test for their subsequent check-up.

No.	Self-sampling Questions	Agree	Neutral	Disagree

		n (%)	n (%)	n (%)
1	I thought the instructions were clear	92 (94.8)	0 (0.0)	5 (5.2)
2	It was easy to do the swab	91 (93.8)	1 (1.0)	5 (5.2)
3	Taking the sample with the swab was painful	12 (12.4)	8 (8.2)	77 (79.4)
4	Taking the sample was uncomfortable to do	11 (11.4)	4 (4.1)	82 (84.5)
5	I felt embarrassed doing the self-sampling	9 (9.3)	1 (1.0)	87 (89.7)
6	It was convenient to do without having to undergo a Pap Test	89 (91.7)	3 (3.1)	5 (5.2)
7	I am confident I did it correctly	90 (92.8)	4 (4.1)	3 (3.1)
8	I want to use this method next time	92 (94.8)	2 (2.1)	3 (3.1)
9	I prefer to do this at home	64 (66.0)	15 (15.5)	18 (18.5)
10	I would recommend this method to other women	91 (93.8)	3 (3.1)	3 (3.1)
11	I trust that the result of this self-sampling will be accurate	74 (76.3)	19 (19.6)	4 (4.1)
12	I would like to attend for a proper Pap test in clinic next time	53 (54.6)	23 (23.7)	21 (21.7)

Table 5. Acceptability of HPV self-sampling among non-attendees who participated in HPV self-sampling at JPSHC, Brunei (Jan–Dec 2019). Responses from all respondents for Q2 (n = 97) were included.

Among the 97 samples taken, nine (9.3%) tested positive for hr-HPV: one was positive for HPV 16 and eight were positive for non-HPV 16/18 HPV genotype. Upon follow-up cytology, only one participant had a normal cytological test result, whilst another participant with non-16/18 HPV genotype was found to have CIN 3 with glandular involvement following a confirmatory biopsy. No significant differences were observed when comparing the sociodemographic characteristics between those who tested hr-HPV positive and those who tested hr-negative (Table S2).

Discussion

This two-part pilot study explored the reasons for cervical screening non-attendance among Bruneian women and whether HPV self-sampling is a viable alternative for the non-attendees. Our findings highlight three important points to consider for improving both screening uptake and detection of cervical cancer.

First, our findings suggest that it is necessary to provide accurate information among Bruneian women on cervical cancer, the importance of screening and addressing any misconceptions about the Pap test. Important facts to relay include the slow development from pre-cancerous changes to cervical cancer, that pre-cancerous changes are highly treatable, and that screening will help in early detection and thus facilitate successful treatment. This is evident in our study, where emotional barriers (fear of unfavourable test results and embarrassment) were the most common major reasons of screening non-attendance. Many women have misconceptions about abnormal Pap test results by relating them to cervical cancer diagnoses [23]. It is not surprising then that almost two-thirds of the women who cited this as their main barrier declined to take part in HPV self-sampling part. As our study participants are predominantly Malays and thus of Islamic faith, religious and cultural modesty could also be a contributing factor for embarrassment among Muslim women [24].

Lack of information or knowledge has been suggested to reduce women's concerns towards cervical cancer [25] and whether to continue attending cervical screening [26]. Although fear, embarrassment and other psychosocial barriers may play a large role at the onset of screening programme, its role diminishes over time with increasing education and knowledge of screening [27]. Educational interventions could also benefit the small group of women who cited menopause, cessation of child-bearing and having had HPV vaccination as reasons for not attending screening.

Promoting cervical cancer awareness could also impact non-attendees' decision to participate in HPV self-sampling. In our study, we observed those who agree that they are susceptible to cervical

cancer were significantly more likely to participate in HPV self-sampling. This suggests that perceived susceptibility could be an important factor for self-sampling participation, whereby those who do not perceive themselves as susceptible were less likely to engage in preventative behaviours [25,28,29]. Perceived susceptibility can be increased through education to improve their beliefs on the necessity of screening [30]. We suggest that such information could be more effectively disseminated as simple health messages endorsed by Brunei's Ministry of Health via website, social media platforms, and the BruHealth application [31] developed by the Brunei government as a public engagement tool during the COVID-19 pandemic.

Second, we observed high acceptability of HPV self-sampling among our participants. Indeed, meta-analyses have indicated strong acceptance of self-sampling and a preference for the latter over clinician sampling [32], mainly due to logistical reasons [33]. Implementing HPV self-sampling in screening programmes have been shown to increase the screening uptake among non-attendees [3,4,7], and also increases the detection of CIN 2+ lesions [8,9]. Providing HPV self-sampling as a cervical cancer screening option could also encourage those, whose main reason for not attending was fear of pain due to previous experience, to attend screening. This reason, also common in our study, was reported as a factor for avoiding screening [34] and is suggested to predict future screening uptake [35]. Among those who joined HPV self-sampling in our study, at least half cited embarrassment, fear of pain or lack of time due to home and/or work commitments as their major reason of not attending screening. This suggest that flexibility to accommodate women's screening method preference [36], such as the option to carry out self-sampling [37], could improve screening uptake.

Notably, only about three-quarters of our self-sampling participants were confident of the result accuracy and less than two-thirds were willing to do the self-sampling at home, suggesting that these participants could be doubting their technique and would prefer to do this in clinics instead.

Also, more than half of them were willing to undergo in-clinic Pap test for their subsequent testing. This is an important consideration if cytology triaging is going to be the country's strategy as a follow-up to HPV screening.

Thirdly, most of the detected hr-HPV genotypes in our study were non-16/18, with only one out of nine participants tested positive for HPV 16. Even though our sample size is small, this result suggests that it may not be accurate to assume HPV 16 or 18 as common hr-HPV genotypes in Brunei, although this is true in the global context [38]. Other studies have detected a significant percentage of non-16/18 hr-HPV genotypes, suggesting the presence of region-specific heterogeneity in the HPV genotype distribution [38–42]. Also, variation in HPV distribution among different ethnic groups has been reported in an American study [43], although reasons for these differences are unclear. Our finding has potential implication on Brunei's national school-based HPV vaccination programme which currently provides vaccines which do not confer protection against non-16/18 genotypes. Providing vaccines that confers protection against nine hr-HPV genotypes [44] could be a better alternative for Bruneian females. Larger population-based studies to understand the distribution of HPV genotypes among Bruneian women will be crucial to determine the efficacy or impact of the current vaccines.

A major limitation for this study is that non-attendees from only one health center were recruited, thus our results are not representative of the adult female population in Brunei. Moreover, the validity of our findings could be compromised due to the small sample size. Our study findings, even at this pilot stage, could encourage stakeholders to conduct similar studies with larger population coverage. Also, as this study relied on the self-reported history of previous Pap test attendance, we might have missed recruiting those who may have forgotten their last Pap test date.

In conclusion, our findings indicate the need to further promote education and awareness towards cervical cancer and its screening process. Reasons of cervical cancer screening non-attendance were mainly related to emotional and logistical factors. As we found high acceptance towards HPV self-sampling, this could be adopted as an alternative for women who refrain from Pap test. Our high detection of non-16/18 HPV genotypes suggest high prevalence of other hr-HPV genotypes in Brunei. Future larger studies involving more Bruneian women can be done to verify our results. Follow-up studies should also be done to consider HPV testing as the suitable method for cervical cancer screening.

Acknowledgements

The authors would like to thank the JPSHC staff who have assisted in participant recruitment and questionnaire distribution.

Funding

Funding for this study was obtained from the Ministry of Health, Brunei Darussalam.

Author contributions

Liling Chaw: Conceptualization, Methodology, Data curation, Formal analysis, Supervision, Writing - original draft, Writing - review & editing

Shirley HF Lee: Visualization, Writing - original draft, Writing - review & editing

Nurul Iffah Hazwani Ja'afar: Investigation, Data curation, Writing - original draft

Edwin Lim: Conceptualization, Methodology, Resources, Funding acquisition, Supervision, Writing - review & editing

Roslin Sharbawi: Conceptualization, Methodology, Resources, Funding acquisition, Investigation, Project administration, Supervision, Writing - original draft, Writing - review & editing

References

1. World Health Organization. Cervical cancer. 2018 [cited 10 Aug 2020]. Available: https://www.who.int/health-topics/cervical-cancer#tab=tab_1
2. Gustafsson L, Pontén J, Zack M, Adami H-O. International incidence rates of invasive cervical cancer after introduction of cytological screening. Cancer Causes Control. 1997;8: 755–763. doi:10.1023/A:1018435522475
3. Yeh PT, Kennedy CE, Vuyst H de, Narasimhan M. Self-sampling for human papillomavirus (HPV) testing: a systematic review and meta-analysis. BMJ Glob Heal. 2019;4: e001351. doi:10.1136/BMJGH-2018-001351
4. Racey C, Withrow D, Gesink D. Self-collected HPV testing improves participation in cervical cancer screening: a systematic review and meta-analysis. Can J Public Health. 2013;104: e159-66. doi:10.1007/BF03405681
5. Maza M, Melendez M, Masch R, Alfaro K, Chacon A, Gonzalez E, et al. Acceptability of self-sampling and human papillomavirus testing among non-attenders of cervical cancer screening programs in El Salvador. Prev Med (Baltim). 2018. doi:10.1016/j.ypmed.2018.06.017
6. Sancho-Garnier H, Tamalet C, Halfon P, Leandri FX, Retraite L Le, Djoufelkit K, et al. HPV self-sampling or the Pap-smear: A randomized study among cervical screening nonattenders from lower socioeconomic groups in France. Int J Cancer. 2013. doi:10.1002/ijc.28283
7. Arrossi S, Thouyaret L, Herrero R, Campanera A, Magdaleno A, Cuberli M, et al. Effect of self-collection of HPV DNA offered by community health workers at home visits on uptake of screening for cervical cancer (the EMA study): A population-based cluster-randomised trial. Lancet Glob Heal. 2015;3: e85–e94. doi:10.1016/S2214-109X(14)70354-7
8. Gustavsson I, Aarnio R, Berggrund M, Hedlund-Lindberg J, Strand A-S, Sanner K, et al. Randomised study shows that repeated self-sampling and HPV test has more than two-fold

higher detection rate of women with CIN2+ histology than Pap smear cytology. Br J Cancer. 2018;118: 896–904. doi:10.1038/bjc.2017.485

9. Arrossi S, Paolino M, Laudi R, Gago J, Campanera A, Marín O, et al. Programmatic human papillomavirus testing in cervical cancer prevention in the Jujuy Demonstration Project in Argentina: a population-based, before-and-after retrospective cohort study. Lancet Glob Heal. 2019;7: e772–e783. doi:10.1016/S2214-109X(19)30048-8

10. Chrysostomou AC, Stylianou DC, Constantinidou A, Kostrikis LG. Cervical cancer screening programs in Europe: The transition towards HPV vaccination and population-based HPV testing. Viruses. 2018;10. doi:10.3390/v10120729

11. Landy R, Pesola F, Castañón A, Sasieni P. Impact of cervical screening on cervical cancer mortality: Estimation using stage-specific results from a nested case-control study. Br J Cancer. 2016;115: 1140–1146. doi:10.1038/bjc.2016.290

12. Canfell K, Sitas F, Beral V. Cervical cancer in Australia and the United Kingdom: Comparison of screening policy and uptake, and cancer incidence and mortality. Med J Aust. 2006;185: 482–486. doi:10.5694/j.1326-5377.2006.tb00661.x

13. Ministry of Health Brunei Darussalam. Health Information Booklet 2017 (Second Revision). 2019 [cited 11 Feb 2020]. Available: http://moh.gov.bn/SitePages/Health Information Booklet.aspx

14. Arbyn M, Weiderpass E, Bruni L, de Sanjosé S, Saraiya M, Ferlay J, et al. Estimates of incidence and mortality of cervical cancer in 2018: a worldwide analysis. Lancet Glob Heal. 2020;8: e191–e203. doi:10.1016/S2214-109X(19)30482-6

15. Chaw LL, Lim STW, Md Yussof SR. Human Papillomavirus vaccine coverage among female students in Brunei Darussalam: results from the first 4 years of the national school-based vaccination programme. Heliyon. 2019;5. doi:10.1016/j.heliyon.2019.e02588

16. Peto PJ, Gilham PC, Fletcher O, Matthews FE. The cervical cancer epidemic that screening has prevented in the UK. Lancet. 2004;364: 249–256. doi:10.1016/S0140-6736(04)16674-9

17. Bosgraaf RP, Ketelaars PJW, Verhoef VMJ, Massuger LFAG, Meijer CJLM, Melchers WJG, et al. Reasons for non-attendance to cervical screening and preferences for HPV self-sampling in Dutch women. Prev Med (Baltim). 2014. doi:10.1016/j.ypmed.2014.04.011

18. Virtanen A, Nieminen P, Niironen M, Luostarinen T, Anttila A. Self-sampling experiences among non-attendees to cervical screening. Gynecol Oncol. 2014;135: 487–494. doi:10.1016/j.ygyno.2014.09.019

19. Bayu H, Berhe Y, Mulat A, Alemu A. Cervical Cancer Screening Service Uptake and Associated Factors among Age Eligible Women in Mekelle Zone, Northern Ethiopia, 2015: A Community Based Study Using Health Belief Model. Grce M, editor. PLoS One. 2016;11: e0149908. doi:10.1371/journal.pone.0149908

20. Sultana F, Mullins R, English DR, Simpson JA, Drennan KT, Heley S, et al. Women's experience with home-based self-sampling for human papillomavirus testing. BMC Cancer. 2015;15: 849. doi:10.1186/s12885-015-1804-x

21. The Hague: Health Council of the Netherlands. Health Council of the Netherlands Population screening for cervical cancer. 2011;2011/07E. Available: https://www.gezondheidsraad.nl/sites/default/files/201107E_PopulationSCC_0.pdf

22. R Core Team. R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria; 2020. Available: http://www.r-project.org/

23. Fylan F. Screening for cervical cancer: a review of women's attitudes, knowledge, and behaviour. Br J Gen Pract. 1998;48: 1509–14.

24. Ali S, Skirton H, Clark MT, Donaldson C. Integrative review of cervical cancer screening in Western Asian and Middle Eastern Arab countries. Nurs Heal Sci. 2017;19: 414–426. doi:10.1111/nhs.12374

25. Agurto I, Arrossi S, White S, Coffey P, Dzuba I, Bingham A, et al. Involving the community in cervical cancer prevention programs. Int J Gynaecol Obstet. 2005;89 Suppl 2: S38-45. doi:10.1016/j.ijgo.2005.01.015

26. Chorley AJ, Marlow LA V, Forster AS, Haddrell JB, Waller J. Experiences of cervical screening and barriers to participation in the context of an organised programme: a systematic review and thematic synthesis. Psychooncology. 2017;26: 161–172. doi:10.1002/pon.4126

27. Teng FF, Mitchell SM, Sekikubo M, Biryabarema C, Byamugisha JK, Steinberg M, et al. Understanding the role of embarrassment in gynaecological screening: A qualitative study from the ASPIRE cervical cancer screening project in Uganda. BMJ Open. 2014. doi:10.1136/bmjopen-2014-004783

28. Shirazi Zadeh Mehraban S, Namdar A, Naghizadeh MM. Assessment of Preventive Behavior for Cervical Cancer with the Health Belief Model. Asian Pac J Cancer Prev. 2018;19: 2155–2163. doi:10.22034/APJCP.2018.19.8.2155

29. Tapera R, Manyala E, Erick P, Maswabi TM, Tumoyagae T, Letsholo B, et al. Knowledge and Attitudes towards Cervical Cancer Screening amongst University of Botswana Female Students. Asian Pac J Cancer Prev. 2017;18: 2445–2450. doi:10.22034/APJCP.2017.18.9.2445

30. Khademolhosseini F, Noroozi A, Tahmasebi R. The Effect of Health Belief Model-Based Education through Telegram Instant Messaging Services on Pap smear performance. Asian Pac J Cancer Prev. 2017;18: 2221–2226. doi:10.22034/APJCP.2017.18.8.2221

31. Ministry of Health Brunei. BruHealth. 2020 [cited 21 Dec 2020]. Available: http://www.moh.gov.bn/SitePages/bruhealth.aspx

32. Nelson EJ, Maynard BR, Loux T, Fatla J, Gordon R, Arnold LD. The acceptability of self-sampled screening for HPV DNA: A systematic review and meta-analysis. Sexually Transmitted Infections. 2017. doi:10.1136/sextrans-2016-052609

33. Lorenzi NPC, Termini L, Longatto Filho A, Tacla M, de Aguiar LM, Beldi MC, et al. Age-related acceptability of vaginal self-sampling in cervical cancer screening at two university hospitals: a pilot cross-sectional study. BMC Public Health. 2019;19: 963. doi:10.1186/s12889-019-7292-1

34. Ebu NI, Mupepi SC, Siakwa MP, Sampselle CM. Knowledge, practice, and barriers toward

cervical cancer screening in Elmina, Southern Ghana. Int J Womens Health. 2015;7: 31–39. doi:10.2147/IJWH.S71797

35. Seow A, Wong ML, Smith WCS, Lee HP. Beliefs and Attitudes as Determinants of Cervical Cancer Screening: A Community-Based Study in Singapore. Preventive Medicine. 1995. pp. 134–141. doi:10.1006/pmed.1995.1026

36. Bansil P, Wittet S, Lim JL, Winkler JL, Paul P, Jeronimo J. Acceptability of self-collection sampling for HPV-DNA testing in low-resource settings: a mixed methods approach. BMC Public Health. 2014;14: 596. doi:10.1186/1471-2458-14-596

37. Jeronimo J, Perkins RB, Scalici J, Pierce JY. Should Self-Sampling Be an Option for Women in the United States? J Low Genit Tract Dis. 2019;23: 54. doi:10.1097/LGT.0000000000000453

38. Albawardi A, Quddus MR, Al Awar S, Almarzooqi S. Frequency of rare and multi viral high-risk HPV types infection in cervical high grade squamous intraepithelial lesions in a non-native dominant middle eastern country: A polymerase chain reaction-based pilot study. Diagn Pathol. 2018. doi:10.1186/s13000-018-0716-x

39. Zeng Z, Yang H, Li Z, He X, Griffith CC, Chen X, et al. Prevalence and Genotype Distribution of HPV Infection in China: Analysis of 51,345 HPV Genotyping Results from China's Largest CAP Certified Laboratory. J Cancer. 2016. doi:10.7150/jca.14971

40. Khoo SP, Bhoo-Pathy N, Yap SH, Anwar Shafii MK, Hairizan Nasir N, Belinson J, et al. Prevalence and sociodemographic correlates of cervicovaginal human papillomavirus (HPV) carriage in a cross-sectional, multiethnic, community-based female Asian population. Sex Transm Infect. 2018. doi:10.1136/sextrans-2017-053320

41. Peng RR, Li HM, Chang H, Li JH, Wang AL, Chen XS. Prevalence and genotype distribution of cervical human papillomavirus infection among female sex workers in Asia: A systematic literature review and meta-analysis. Sexual Health. 2012. doi:10.1071/SH11066

42. Al-Awadhi R, Chehadeh W, Jaragh M, Al-Shaheen A, Sharma P, Kapila K. Distribution of human papillomavirus among women with abnormal cervical cytology in Kuwait. Diagn

Cytopathol. 2013. doi:10.1002/dc.21778

43. Keller MJ, Burk RD, Massad LS, Eltoum IE, Hessol NA, Anastos K, et al. Racial differences in human papilloma virus types amongst United States women with HIV and cervical precancer. AIDS. 2018. doi:10.1097/QAD.0000000000002005

44. Yusupov A, Popovsky D, Mahmood L, Kim AS, Akman AE, Yuan H. The nonavalent vaccine: a review of high-risk HPVs and a plea to the CDC. Am J Stem Cells. 2019.

Supplementary information

Table S1. Responses on their major and minor reasons for not attending cervical cancer screening among non-attendees at JPSHC, Brunei (Jan – Dec 2019)

No.	Reasons for not attending screening	Major reason* n (%)	Minor reason^ n (%)
1	I feel embarrassed being examined by a doctor or nurse	26 (14.9)	36 (20.7)
2	I am scared of pain because of previous bad experience(s)	16 (9.2)	13 (7.5)
3	I am afraid of getting a bad result	28 (16.1)	35 (20.1)
4	I can't find the time as I'm too busy at home	18 (10.3)	28 (16.1)
5	I can't find the time as I'm too busy at work	16 (9.2)	36 (20.7)
6	Nobody to send me to clinic	2 (1.2)	11 (6.3)
7	Nobody is looking after child(ren) at home	2 (1.2)	13 (7.5)
8	Difficult to get permission from employer	8 (4.6)	14 (8.1)
9	I have never heard of a Pap Test	7 (4.0)	8 (4.6)
10	I don't know what cervical cancer is	1 (0.6)	15 (8.6)
11	Not necessary as I am healthy	4 (2.3)	15 (8.6)
12	Not necessary as I am not child-bearing anymore	4 (2.3)	14 (8.0)
13	Not necessary as I don't have menses anymore	4 (2.3)	11 (6.3)
14	Not necessary as I don't have a partner anymore	0 (0.0)	1 (0.6)
15	Not necessary as I have already had my HPV vaccination	2 (1.2)	2 (1.2)
16	I have forgotten about it	6 (3.4)	2 (1.2)
17	I did not receive any invitation	6 (3.4)	0 (0.0)
18	Others	15 (8.6)	4 (2.3)
	Missing	9 (5.1)	0 (0.0)

*One response for each participant
^Multiple responses were allowed

Table S2. Socio demographic characteristics and comparison between screening non-attendees who tested positive and negative for hr-HPV at JPSHC, Brunei (Jan – Dec 2019),

Characteristics		Total study population (n = 174) n (%)	Joined self-sampling (n = 97) n (%)	HPV positive (n = 9) n (%)	HPV negative (n = 88) n (%)	p-value
Median age in years (IQR)		45 (15.25)	41.0 (17)	35.0 (10)	41.5 (16.5)	0.115
Age-group	20 - 24	3 (1.7)	3 (3.1)	0 (0.0)	3 (3.4)	0.637
	25 - 29	20 (11.5)	15 (15.5)	3 (33.4)	12 (13.6)	
	30 - 34	14 (8.1)	10 (10.3)	1 (11.1)	9 (10.2)	
	35 - 39	28 (16.1)	18 (18.5)	3 (33.4)	15 (17.1)	
	40 - 44	18 (10.3)	11 (11.3)	0 (0.0)	11 (12.5)	
	45 - 49	27 (15.5)	12 (12.4)	1 (11.1)	11 (12.5)	
	50 - 54	35 (20.1)	15 (15.5)	0 (0.0)	15 (17.1)	
	55 - 59	14 (8.1)	10 (10.3)	1 (11.1)	9 (10.2)	
	> 60	13 (7.5)	3 (3.1)	0 (0.0)	3 (3.4)	
	Missing	2 (1.1)	0 (0.0)	0 (0.0)	0 (0.0)	
Race	Malay	161 (92.5)	90 (92.8)	8 (88.8)	82 (93.2)	0.289
	Chinese	6 (3.5)	4 (4.1)	0 (0.0)	4 (4.5)	
	Other	7 (4.0)	3 (3.1)	1 (11.1)	2 (2.3)	
Education level	Primary school	16 (9.2)	10 (10.3)	2 (22.2)	8 (9.1)	0.456
	Secondary school	96 (55.2)	49 (50.5)	4 (44.5)	45 (51.1)	
	College / university	57 (32.7)	35 (36.1)	3 (33.3)	32 (36.4)	
	Missing	5 (2.9)	3 (3.1)	0 (0.0)	3 (3.4)	
Marital status	Married	157 (90.2)	91 (93.8)	9 (100)	82 (93.2)	1
	Divorced	8 (4.6)	2 (2.1)	0 (0.0)	2 (2.3)	
	Widowed	9 (5.2)	4 (4.1)	0 (0.0)	4 (4.5)	
Occupation	Housewife	64 (36.8)	39 (40.2)	5 (55.6)	34 (38.6)	0.862
	Government employee	67 (38.5)	41 (42.3)	3 (33.3)	38 (43.2)	
	Private employee	31 (17.8)	13 (13.4)	1 (11.1)	12 (13.6)	
	Retired	9 (5.2)	3 (3.1)	0 (0.0)	3 (3.4)	
	Unemployed	1 (0.6)	1 (1.0)	0 (0.0)	1 (1.2)	
	Other	2 (1.1)	0 (0.0)	0 (0.0)	0 (0.0)	
Household income	< $500	27 (15.5)	15 (15.5)	1 (11.1)	14 (15.9)	0.612
	$500 < $999	27 (15.5)	12 (12.4)	0 (0.0)	12 (13.6)	

	$1000-$1999	40 (23.0)	22 (22.7)	3 (33.3)	19 (21.6)	
	$2000-$2999	19 (10.9)	14 (14.3)	0 (0.0)	14 (15.9)	
	$3000-$5000	24 (13.8)	15 (15.5)	2 (22.3)	13 (14.8)	
	>$5000	3 (1.7)	2 (2.1)	0 (0.0)	2 (2.3)	
	Missing	34 (19.5)	17 (17.5)	3 (33.3)	14 (15.9)	
No of births	0	27 (15.5)	17 (17.5)	3 (33.3)	14 (15.9)	0.453
	1	19 (10.9)	14 (14.4)	1 (11.1)	13 (14.8)	
	2	22 (12.1)	14 (14.4)	0 (0.0)	14 (15.9)	
	3 or more	105 (60.3)	51 (52.6)	5 (55.6)	46 (52.3)	
	Missing	2 (1.2)	1 (1.1)	0 (0.0)	1 (1.1)	
Last Pap test done	Never	41 (23.6)	29 (29.9)	4 (44.4)	25 (28.4)	0.313
	4-10 years	91 (52.3)	48 (49.5)	4 (44.4)	44 (50.0)	
	> 10 years	36 (20.7)	15 (15.5)	0 (0.0)	15 (17.1)	
	Missing	6 (3.4)	5 (5.1)	1 (11.2)	4 (4.5)	
Completed HPV vaccination	Never	95 (54.6)	50 (51.6)	6 (66.7)	44 (50.0)	0.899
	Yes	27 (15.5)	16 (16.5)	1 (11.1)	15 (17.1)	
	No	41 (23.6)	26 (26.8)	2 (22.2)	24 (27.3)	
	Missing	11 (6.3)	5 (5.1)	0 (0.0)	5 (5.6)	